Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29466485 | 0.79 | NPC1 (0.52) | ALDH1A1NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL16960567 | 0.79 | ALDH1A1 (0.35) | ALDH1A1NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL3445603 | 0.79 | NPC1 (0.41) | ALDH1A1NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL166193 | 0.79 | NPC1 (0.52) | ALDH1A1NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL31583030 | 0.79 | NPC1 (0.41) | ALDH1A1NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL23978028 | 0.79 | NPC1 (0.41) | ALDH1A1NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL28879856 | 0.79 | ALDH1A1 (0.47) | ALDH1A1NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL1548711 | 0.78 | NPC1 (0.43) | ALDH1A1NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL16962049 | 0.77 | ALDH1A1 (0.39) | ALDH1A1NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL2359084 | 0.77 | NPC1 (0.40) | ALDH1A1NPC1RAB9ASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10451967-B2 | Acid- and radical-generating agent and method for generating acid and radical | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2019-10-22 | — | — | US | disclosed |
| US-20160342084-A1 | ACID- AND RADICAL-GENERATING AGENT AND METHOD FOR GENERATING ACID AND RADICAL | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2016-11-24 | — | — | US | disclosed |
| CN-103917522-B | Process for producing N- (hetero) arylazoles | 高砂香料工业株式会社 | 2016-06-15 | — | — | CN | disclosed |
| US-9233922-B2 | Process for producing N-(hetero)arylazoles | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-01-12 | — | — | US | disclosed |
| EP-2736881-B1 | PROCESS FOR PRODUCING N-(HETERO)ARYLAZOLES | TAKASAGO PERFUMERY CO LTD (JP) | 2015-10-07 | — | — | EP | disclosed |
| US-20140371461-A1 | PROCESS FOR PRODUCING N-(HETERO)ARYLAZOLES | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-12-18 | — | — | US | disclosed |
| CN-103917522-A | Process for producing N- (hetero) arylazoles | TAKASAGO PERFUMERY CO LTD | 2014-07-09 | — | — | CN | disclosed |
| EP-2736881-A1 | PROCESS FOR PRODUCING N-(HETERO)ARYLAZOLES | Takasago International Corporation (JP) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013032035-A1 | PROCESS FOR PRODUCING N-(HETERO)ARYLAZOLES | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-03-07 | — | — | WO | disclosed |
| EP-1778665-A1 | PROCESS FOR THE PREPARATION OF 11-[(Z)-3-(DIMETHYLAMINO)PROPYLIDENE]-6,11-DIHYDRO-DIBENZ[B,E]OXEPIN-2-YL]ACETIC ACID | Urquima S.A. (ES) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006010459-A1 | PROCESS FOR THE PREPARATION OF 11-[(Z)-3-(DIMETHYLAMINO)PROPYLIDENE]-6,11-DIHYDRO-DIBENZ[B,E]OXEPIN-2-YL]-ACETIC ACID | URQUIMA S.A. (ES) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371461-A1 | PROCESS FOR PRODUCING N-(HETERO)ARYLAZOLES | CYP3A4, HCN4, PPOX | ALDH1A1 3167/4885NPC1 3396/4885RAB9A 4035/4885 |
| US-10451967-B2 | Acid- and radical-generating agent and method for generating acid and radical | CBR1, HAO2, CBR3 | ALDH1A1 151/4885NPC1 3627/4885RAB9A 1800/4885 |
| US-20160342084-A1 | ACID- AND RADICAL-GENERATING AGENT AND METHOD FOR GENERATING ACID AND RADICAL | CBR1, HAO2, CBR3 | ALDH1A1 151/4885NPC1 3627/4885RAB9A 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.